[ad_1] Our study highlighted in @RetinalPhys – #Suprachoroidal delivery is of interest given #clinicaltrials of corticosteroid in #macular edema, tyrosine kinase inhibitor in wet #AMD, #genetherapy in wet AMD & #diabetic retinopathy, viral nanoparticle conjugates in choroidal melanoma: https://t.co/6po57PW5ux [ad_2] Source by Thomas Ciulla, MD, …

[ad_1] Recently published on a leading cause of #vision loss. #Diabetic macular edema treatment burden remains a significant barrier to meaningfully positive real world outcomes. Longer acting and more effective #treatments are needed… #retina #diabetes https://t.co/BMsesiBPCL [ad_2] Source by Thomas Ciulla, MD, MBA Return to …

[ad_1] Just published on suprachoroidal drug delivery: “Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders” https://t.co/fyTjYAo5gw #eyes #ophthalmology #retina #macula #clinicalresearch #GeneTherapy #biotech https://t.co/EIUMer01Fj [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Exciting news from Indianapolis-based Biotech, Eli Lilly… https://t.co/3qTHNQkfjs [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Pleased to work with Vestrum on clinical data analytics… https://t.co/4uIFiCI2NM https://t.co/2KDXdfUQba [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.